Evidence map›Paper›PMID 35361228›Full record

ArticleSubstance abuse treatment, prevention, and policy2022

Factors associated with take-home naloxone kit usage in British Columbia: an analysis of administrative data.

Victor Lei, Max Ferguson, Rachael Geiger, Sierra Williams, Lisa Liu, Jane A Buxton

Open access · goldAbstract read
In one paragraph

Article in Substance abuse treatment, prevention, and policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Guideline
  2. Article
  3. North America's fentanyl death crisis: Selected lessons for Europe's future?Nordisk alkohol- & narkotikatidskrift : NAT · 2024
    Article
  4. Article
  5. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023
    Article
  6. Guidance on take-home naloxone distribution and use by community overdose responders in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Victor LeiSchool of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
Max FergusonBC Centre for Disease Control, Vancouver, BC, Canada.
Rachael GeigerSchool of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
Sierra WilliamsBC Centre for Disease Control, Vancouver, BC, Canada.
Lisa LiuBC Centre for Disease Control, Vancouver, BC, Canada.
Jane A BuxtonSchool of Population and Public Health, University of British Columbia, Vancouver, BC, Canada. jane.buxton@bccdc.ca.
BC Centre for Disease Control · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe British Columbia (BC) Take-Home Naloxone (THN) program provides naloxone to people at risk of experiencing or witnessing an opioid overdose for use in reversing suspected overdose events. This study seeks to examine trends and correlates of individuals obtaining a THN kit in BC between 2017 and 2020.

methodsRecords of THN kits distributed between 2017 and 2020 were the primary source of data for this analysis. Frequency tables were used to describe characteristics of people obtaining kits from THN sites. Correlates of individuals obtaining a THN kit to replace a previous kit reported as used to reverse an overdose were assessed with multivariate logistic regression.

resultsBetween January 1, 2017, and December 31, 2020, 240,606 THN kits were reported distributed by registered sites to members of the public, with 90,011 records indicating that a kit was obtained to replace a previous kit that had been used to reverse an overdose. There was a significant trend in increasing kits reported used by year (p < 0.01). The kit recipient's risk of overdose was a significant predictor of having reported using a THN kit, and the strength of the association was dependent on gender (Male: Adjusted odds ratio (AOR) 5.37 [95% confidence interval (CI) 5.08 - 5.67]; Female: AOR 8.35 [95% CI 7.90 - 8.82]; Trans and gender expansive: AOR 3.68 [95% CI 2.82 - 4.79]).

conclusionsBetween 2017 and 2020, THN kits were used to reverse tens of thousands of overdose events in BC, with people at risk of overdose (i.e. people who use drugs [PWUD]) having greater odds of using a kit to reverse an overdose than those not at risk. Thus, PWUD are responsible for reversing the vast majority of overdoses. THN kits are being distributed to the people who use them most. However, additional strategies in conjunction with community-based naloxone distribution programs are needed to address the rising number of illicit drug toxicity deaths.

Indexed as

Drug OverdoseIllicit DrugsBritish ColumbiaFemaleHumansMaleNaloxoneNarcotic AntagonistsIllicit DrugsNaloxoneNarcotic AntagonistsHarm reductionNaloxoneOpioid antagonistOverdoseTake-home naloxoneToxicity

Identifiers

PMID35361228
PMCPMC8968772
OpenAlexW4220870166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.